UNITED THERAPEUTICS Corp
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
UTHR$588.61+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| Cash flows from operating activities: | ||
| Net income | $893.8 | $767.7 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 52.8 | 39.5 |
| Share-based compensation expense | 117.0 | 22.5 |
| Impairment of property, plant, and equipment | — | 3.6 |
| Other | (21.7) | 0.1 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (62.9) | (38.2) |
| Inventories | (35.3) | (6.6) |
| Accounts payable and accrued expenses | 60.7 | 80.2 |
| Other assets and liabilities | (18.5) | (41.5) |
| Net cash provided by operating activities | 985.9 | 827.3 |
| Cash flows from investing activities: | ||
| Purchases of property, plant, and equipment | (159.8) | (151.7) |
| Deposits | (22.5) | (14.3) |
| Purchases of available-for-sale debt securities | (1,167.6) | (2,206.3) |
| Maturities of available-for-sale debt securities | 1,059.0 | 1,610.6 |
| Sales of available-for-sale debt securities | 831.8 | — |
| Purchase of investment in privately-held company | (0.5) | — |
| Net cash provided by (used in) investing activities | 540.4 | (761.7) |
| Cash flows from financing activities: | ||
| Payments to repurchase common stock | (1,000.0) | — |
| Repayment of line of credit | (300.0) | — |
| Payments of debt issuance costs | (2.7) | (2.7) |
| Proceeds from the exercise of stock options | 126.8 | 90.7 |
| Proceeds from the issuance of stock under ESPP | 7.7 | 6.6 |
| RSUs withheld for taxes | (11.9) | (13.7) |
| Net cash (used in) provided by financing activities | (1,180.1) | 80.9 |
| Net increase in cash and cash equivalents | $346.2 | $146.5 |
| Cash and cash equivalents, beginning of period | 1,207.7 | 961.2 |
| Cash and cash equivalents, end of period | $1,553.9 | $1,107.7 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $33.0 | $41.8 |
| Cash paid for income taxes | $289.3 | $235.9 |
| Non-cash investing and financing activities: | ||
| Non-cash additions to property, plant, and equipment | $23.6 | $34.8 |
| Measurement period adjustment to purchase price | $(1.4) | $— |
| Excise tax on net share repurchase | $5.8 | $— |
| Receivable from maturity of available-for-sale debt securities | $— | $60.0 |
| 8 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.